PBAC's latest decision on Dostarlimab: Recommended with restriction (2025). Considered for Treatment of primary advanced or first recurrent mismatch repair proficient (pMMR) endometrial cancer in combination with carboplatin and paclitaxel, in patients unsuitable for curative surgical resection or radiotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
4
first 2022
Submissions
4
2022 → 2025
Eligible population
Adults with primary advanced or first recurrent pMMR endometrial cancer unsuitable for curative surgical resection or radiotherapy, either treatment-naïve or with recurrence/progression >6 months after prior neoadjuvant/adjuvant systemic therapy, and no prior PD-1/PD-L1 inhibitor treatment, with ECOG performance status ≤1.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Pivotal trial size
189 patients
Key trials
RUBY
Comparator
carboplatin and paclitaxel alone
Economic model
CUA
ICER note
ICER value is redacted/commercially sensitive; the document states the nominal ICER is similar to the November 2023 submission for dMMR but is not numerically disclosed.
Submission history
Mar 2022: Recommended with restriction · Authority Required
Mar 2023: Recommended with restriction · Restricted
Nov 2023: Recommended with restriction · Authority Required
May 2025: Recommended with restriction · Authority Required